Details

Autor(en) / Beteiligte

• Adenis, Antoine
• Bouché, Olivier
• Bertucci, François
• Kalbacher, Elsa
• Fournier, Charles
• Cassier, Philippe
• Collard, Olivier
• Bay, Jacques-Olivier
• Italiano, Antoine
• Chevreau, Christine
• Clisant, Stéphanie
• Kramar, Andrew
• Blay, Jean-Yves
• Penel, Nicolas

Titel

Serum creatine kinase increase in patients treated with tyrosine kinase inhibitors for solid tumors

Ist Teil von

• Medical oncology (Northwood, London, England), 2012-12, Vol.29 (4), p.3003-3008

Ort / Verlag

Boston: Springer US

Erscheinungsjahr

2012

Quelle

MEDLINE

Beschreibungen/Notizen

• Regarding the frequency of muscular complains with the use of tyrosine kinase inhibitors (TKIs), we hypothesize that creatine kinase (CK) elevation may be more frequent than usually reported. We conducted a prospective study on patients treated with TKIs for solid tumors, to assess the incidence of CK increase on treatment. Most of the patients (105/155) had a gastrointestinal stromal tumor. Treatments were carried out with the following drugs: imatinib (87 cases); sunitinib (21 cases); HER antagonists (14 cases), other TKIs (15 cases); and imatinib-based combinations (2 cases). Myalgias were found in 50/155 patients (32 %). Fifty-four patients (35 %; 95 %CI, 27–42 %) had elevated CK. According to NCI-CTC grading, there was 49/54 (31 %) grade 1 and 5/54 (3 %) grade 2 (2.5 to 5 times ULN). CK elevation was more frequent with imatinib than with other TKIs (39 cases, 45 % vs. 14 cases, 21 %, respectively; chi-squared test: P  = 0.003), and CK was more likely to be abnormal in patients treated with any TKI for more than 6 months. We found increased CK in about one-third of patients under TKIs for solid tumors, including 3 % of patients with CK as high as 2.5–5 times ULN.